FilingReader Intelligence
Wolwo Bio-Pharmaceutical projects strong first half growth
July 15, 2025 at 10:52 AM UTC•By FilingReader AI
Zhejiang Wolwo Bio-Pharmaceutical expects net profit attributable to shareholders for the first half of 2025 to be between 170 million yuan and 185 million yuan, an increase of 13.92% to 23.97% year-on-year.
Growth is attributed to increased sales of key products, including dust mite drop solution and ragweed pollen sublingual drops, driven by enhanced market promotion.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SZSE:300357•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Wolwo Bio-Pharmaceutical publishes news
Free account required • Unsubscribe anytime